Skip to main content

Biotech ETFs Climb on Biogen’s Promising Clinical Trial

Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB) increased 3.2%, First Trust NYSE Arca Biotechnology...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.